Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™

February 06, 2001

February 4-8, 2001
Sheraton Hotel and Towers, Chicago, IL
Visit us at Posters #332 and 333 (Feb 6th)
-end-
For more information Contact:
Renee Connolly of Noonan/Russo Communications, Inc., 212-696-4455 ext 227,
r.connolly@noonanrusso.com
or
Michael Partridge of Vertex Pharmaceuticals, Incorporated, 617-577-6108
michael_partridge@vpharm.com


Noonan/Russo Communications

Related Protease Inhibitor Articles from Brightsurf:

Oncotarget: Targeting breast cancer metabolism with a novel inhibitor
The Oncotarget author's data suggest in vitro proof-of-concept that supports inhibition of mitochondrial ATP synthase and ROS generation as contributors to the effectiveness of CADD522 in the suppression of tumor growth

Crystal structure of SARS-CoV-2 papain-like protease
The pandemic of coronavirus disease 2019 (COVID-19) is changing the world like never before.

Rare congenital heart defect rescued by protease inhibition
A research team at the Greenwood Genetic Center (GGC) has successfully used small molecules to restore normal heart and valve development in an animal model for Mucolipidosis II (ML II), a rare genetic disorder.

Synthetic drug ebselen could be repurposed to treat SARS-CoV-2 by targeting main protease at distant
The synthetic drug ebselen can bind to both the catalytic region and a previously unknown distant site on the SARS-CoV-2 virus' main protease, according to a molecular simulation analysis of the drug's interactions with this enzyme.

New LAT1 inhibitor can boost cancer treatment
Researchers at the University of Eastern Finland have developed a new and promising drug compound for the treatment of cancer that inhibits natural amino acids from entering cancer cells.

Structure-based design of antiviral drug candidates targets SARS-CoV-2 main protease
A team of Chinese scientists has recently developed two novel compounds that inhibit the SARS-CoV-2 main protease (Mpro) and one of them is a good drug candidate for further clinical studies.

Chinese scientists determine structure of COVID-19 main protease and identify inhibitors
A team of Chinese scientists has reported the high-resolution crystal structure of the main protease (Mpro) of the COVID-19 virus and has identified drugs that may hold promise in combating the virus.

PARP inhibitor drugs can be 'tuned' for better killing of tumor cells
A prospective 'PARP inhibitor' drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report this week in Science.

Sulfonated chitosan studied as potential biodegradable corrosion inhibitor
Hydrate formation has long been a problem for hydrocarbon production in the Arctic.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Protease Inhibitor News and Protease Inhibitor Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.